Mahesh Karande's most recent trade in Omega Therapeutics Inc was a trade of 314,326 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 7, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Omega Therapeutics Inc | Karande Mahesh | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 314,326 | 314,326 | - | - | Stock Option (Right to Buy) | |
Omega Therapeutics Inc | Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 209,551 | 209,551 | - | - | Stock Option (Right to Buy) | |
Omega Therapeutics Inc | Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 170,000 | 170,000 | - | - | Option (Right to Buy) | |
Omega Therapeutics Inc | Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 340,000 | 340,000 | - | - | Option (Right to Buy) | |
Omega Therapeutics Inc | Mahesh Karande | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.53 per share. | 01 Feb 2022 | 11,300 | 117,711 | - | 0.5 | 5,989 | Common Stock |
Omega Therapeutics Inc | Mahesh Karande | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 11,300 | 884,071 | - | - | Option (Right to Buy) |